FMP

FMP

Enter

Citigroup Initiates Coverage on Regeneron Pharmaceuticals with a "Neutral" Rating

- (Last modified: Nov 15, 2024 9:42 AM)

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • Citigroup sets a price target of $895 for Regeneron Pharmaceuticals (NASDAQ:REGN), indicating potential growth.
  • Upcoming clinical data readouts could keep investor interest in Regeneron's pipeline over the next 12 to 24 months.
  • Challenges with Eylea could impact Regeneron's growth, despite the positive outlook for Eylea-HD.

On November 13, 2024, Citigroup initiated coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a "Neutral" rating. Regeneron, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for serious diseases. It competes with other pharmaceutical giants like Amgen and Biogen. At the time of Citigroup's announcement, Regeneron's stock price was $804.33, as reported by StreetInsider.

Citi set a price target of $895 for Regeneron, indicating potential growth from its current price. The analyst highlights that upcoming clinical data readouts are expected to keep investors interested over the next 12 to 24 months. This suggests that Regeneron's pipeline could offer promising developments, which might influence the stock's future performance.

Despite the positive outlook for Eylea-HD, challenges with the standard Eylea could impact the franchise's growth. Eylea is a key product for Regeneron, and any decline in its performance could affect the company's overall growth trajectory. Investors should monitor how these challenges unfold and their impact on Regeneron's financial health.

Regeneron's stock price has seen fluctuations, trading as low as $803.33 and as high as $823.56 today. Over the past year, the stock reached a high of $1,211.20 and a low of $784.96. This volatility reflects the market's response to various factors, including product performance and broader market conditions.

With a market capitalization of approximately $86.93 billion, Regeneron remains a significant player in the biotechnology sector. The trading volume for the day is 589,367 shares, indicating active investor interest. As the company navigates its challenges and opportunities, its stock performance will be closely watched by market participants.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep